Consolidation Chemotherapy for Adults With AML in First Remission: Is There a Best Choice?
Mené sur 1 179 patients atteints d'une leucémie myéloïde aiguë (âge médian : 48 ans), cet essai multicentrique évalue l'efficacité, du point de vue de la survie globale et de la survie sans progression, et la toxicité de l'ajout de mitoxantrone et d'amsacrine à un traitement de consolidation à base de cytarabine à haute dose
The treatment of patients younger than 60 years with acute myeloid leukemia (AML) is divided into two phases: remission induction and postremission therapy.1 Newly diagnosed patients receive socalled induction chemotherapy, with a goal of lowering the presumed 1012 AML cells present at diagnosis to a level at which AML cells are undetectable by morphological analysis in the blood, bone marrow, and elsewhere, to the 109 cells believed to be present at the time of complete remission...
Journal of Clinical Oncology , éditorial en libre accès, 2013